Humira
AbbVie and Mylan reach US marketing agreement for Humira biosimilar
July 18, 2018Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma
AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …
Top Ten most popular articles on Pharmafile.com this week
April 13, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten
It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …
AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3
April 11, 2018Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib
AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …
Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar
April 6, 2018Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma
Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
Boehringer celebrates EU approval of Humira biosimilar
November 14, 2017Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …
Five more biosimilar-free years for AbbVie’s megablockbuster
September 28, 2017Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
AbbVie suffers knock to Humira patent
May 19, 2017Medical Communications, Sales and Marketing AbbVie, Humira, patents
Humira is the largest selling pharmaceutical drug in the world. The treatment for rheumatoid arthritis brought in over $16 billion …
UK High Court rules against AbbVie’s Humira patents
March 6, 2017Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 6, 2017Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …
Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection
February 1, 2017Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab
Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …
Amgen drug pair become first Humira biosimilars to win EU approval
January 30, 2017Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis
Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …
Boehringer steps into Humira race with US and EU biosimilar filings
January 19, 2017Sales and Marketing Boehringer Ingelheim, Humira, biosimilar
Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …
Pfizer announce positive results for Humira biosimilar
January 6, 2017Medical Communications, Research and Development, Sales and Marketing Humira, Pfizer, biosimilar
Pfizer has released the successful Phase 3 results to its biosimilar to AbbVie’s blockbuster Humira, meeting its primary endpoint in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
